Europe Cervical Cancer Test Market Keeps to Growth Trend, States Renub Research in Its Insightful Study Recently Uploaded at MarketPublishers.com
03 Feb 2017 • by Natalie Aster
LONDON – The significantly rising number of incidence of cervical cancer in Europe is the key factor fueling growth of the European cervical cancer market. Nowadays, this disease is amid the most serious public health issues across Europe.
Despite the introduction of cervical cancer vaccination in 21 countries in the European region, still more than 24,000 women have passed away from this disease across Europe.
The current cervical cancer incidence rate registered in Europe stands at 10.6 per 100,000 female population.
As of 2015, Germany, France and the UK were recognized as the largest cervical cancer markets.
Comprehensive research report “Europe Cervical Cancer Test Market, Patients, By Screening Type (Pap Smear, HPV DNA) (United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway, Netherlands)” worked out by Renub Research examines the European market for cervical cancer tests and discloses important details on cervical cancer tests, population and mortality. It provides the market assessment on the basis of screening type (Pap Smear, HPV DNA), explores the situation across the major country-wide markets and also gives access to relevant data on cervical cancer market performance during the period 2001-2011. Future predictions up till 2020 for the regional cervical cancer test market are also available in the report.
The United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway, the Netherlands are amid the country-wide cervical cancer test markets that are thoroughly investigated in this publication.
To find many more reports prepared by Renub Research, kindly, follow to its page.